Breaking Finance News

JMP Securities downgraded Intra-Cellular Therapies (NASDAQ:ITCI) from Outperform to Market Perform in a statement released earlier today.

Yesterday Intra-Cellular Therapies (NASDAQ:ITCI) traded -1.17% lower at $42.35. The company’s 50-day moving average is $40.24 and its two hundred day average is $37.16. With the last close up -58.98% relative to the two hundred day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.01% over the same time. 5,567,863 shares of Intra-Cellular Therapies exchanged hands, up from an average trading volume of 764,584

JMP Securities has downgraded Intra-Cellular Therapies (NASDAQ:ITCI) from Outperform to Market Perform in a statement released on Thursday September 29, 2016.

Previously on 06/02/2016, Piper Jaffray released a statement for Intra-Cellular Therapies (NASDAQ:ITCI) raised the target price from $0.00 to $57.00 that indicated a possible upside of 0.42%.

Recent Performance Chart

Intra-Cellular Therapies (NASDAQ:ITCI)

With a total market value of $0, Intra-Cellular Therapies has 52 week low of $14.44 and a 52 week high of $59.96 .

In addition to JMP Securities reporting its stock price target, a total of 8 brokerages have issued a ratings update on the stock. The consensus target price is $74.25 with three equity analysts rating the company a strong buy, four brokerages rating the company a buy, 0 firms rating the stock a hold, 0 equity analysts rating the company a underperform, and lastly zero firms rating the stock a sell.

More About Intra-Cellular Therapies (NASDAQ:ITCI)

Intra-Cellular Therapies, Inc. (ITI) is a biopharmaceutical company. The Company is focused on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS). The Company's pipeline includes approximately two product candidates in clinical development and two product candidates in advanced pre-clinical testing. Its platform includes ITI-007 platform and phosphodiesterase (PDE) Inhibitor Platform. It is developing its lead drug candidate, ITI-007, for the treatment of schizophrenia, behavioral disturbances associated with dementia, autism and other CNS diseases. Its ITI-007 platform also includes long acting injectable (LAI) program, and IC200131 program for mood and other disorders. Its PDE Inhibitor Platform includes PDE1 program and PDE2 and PDE9 programs.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *